

Radboud Research Rounds

DIPAK1: making a difference to ADPKD patients



Date: 23 August, 2018

Location: Tuinzaal, route 706

DIPAK1 is a 'nierstichting' sponsored consortium that aims at Developing Intervention strategies to halt Progression of Autosomal Dominant Polycystic Kidney Disease. It started in 2011 and joins the research activities of 4 UMC (UMCG, Radboudumc, EMC, LUMC). A major deliverable is a clinical trial that ran for 3 years and randomized 300 ADPKD patients to somatostatin analogues or placebo in an effort to combat renal function decline. This RRR will be devoted to the results of the DIPAK1 study.

- | | |
|-------|--|
| 16:00 | Phenotype of ADPKD in 15 minutes
<i>Jack Wetzels (Radboudumc)</i> |
| 16:20 | ADPKD : role of Polycystin 1 as central molecule in PLD
<i>Dorien Peters (Leiden University Medical Center)</i> |
| 16:45 | Treatment of ADPKD: DIPAK1 study
<i>Ron Gansevoort (University Medical Center Groningen)</i> |
| 17:10 | The liver in ADPKD: DIPAK1 substudy
<i>Rene van Aerts (Radboudumc) / Joost PH Drenth (Radboudumc)</i> |

These lectures are intended for students, post-docs and staff interested in the latest research strategies within a particular theme. Registration is not required. This Radboud Research Round is organized by theme **Renal disorders**.

Next Radboud Research Round **30 August, Inflammatory diseases**.